Implantica presents the fourth quarter 2023 on February 16 at 15:00 CET

If you wish to participate via webcast, please use the following link:     If you wish to participate via webcast, please use the following link:     If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.            Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

If you wish to participate via webcast, please use the following link:    

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.           

Speakers:

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on February 5, 2024 at 09:00 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

The following files are available for download:

Cision View original content:https://www.prnewswire.co.uk/news-releases/implantica-presents-the-fourth-quarter-2023-on-february-16-at-1500-cet-302053060.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;